{"title":"Clostridium butyricum CGMCC 0313.1 improves clinical outcomes of metabolic syndrome in schizophrenic patients.","authors":"Libin Song, Zhihua Zhang, Wenyan Zheng, Yiqi Wang, Yingzi Zhang","doi":"10.62347/DNIL9369","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To primarily analyze the therapeutic effectiveness of <i>Clostridium butyricum</i> CGMCC 0313.1 (CB0313.1) in managing metabolic syndrome (MS) in patients with schizophrenia.</p><p><strong>Methods: </strong>A total of 100 schizophrenic patients with relatively stable conditions admitted were selected. Patients receiving CB0313.1 were assigned to the observation group (n=52), and the others undergoing lifestyle interventions without CB0313.1 were formed the control group (n=48). Additionally, changes in obesity indices, blood sugar (BS) data, lipid profiles, blood pressure (BP), oxidative stress markers, Positive and Negative Syndrome Scale (PANSS) scores, treatment efficacy, and quality of life were evaluated before and after 12 weeks of intervention.</p><p><strong>Results: </strong>After the intervention, the observation group presented significantly greater improvements in oxidative stress reduction, and overall therapeutic efficacy compared to the control group. In addition, the observation group showed more pronounced reductions in obesity indices, BS levels, lipid profiles, BP, and PANSS scores. However, improvements in quality-of-life were comparable between the two groups.</p><p><strong>Conclusion: </strong>CB0313.1 helps enhance the clinical management of MS in schizophrenic patients.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 6","pages":"4399-4408"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261172/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/DNIL9369","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To primarily analyze the therapeutic effectiveness of Clostridium butyricum CGMCC 0313.1 (CB0313.1) in managing metabolic syndrome (MS) in patients with schizophrenia.
Methods: A total of 100 schizophrenic patients with relatively stable conditions admitted were selected. Patients receiving CB0313.1 were assigned to the observation group (n=52), and the others undergoing lifestyle interventions without CB0313.1 were formed the control group (n=48). Additionally, changes in obesity indices, blood sugar (BS) data, lipid profiles, blood pressure (BP), oxidative stress markers, Positive and Negative Syndrome Scale (PANSS) scores, treatment efficacy, and quality of life were evaluated before and after 12 weeks of intervention.
Results: After the intervention, the observation group presented significantly greater improvements in oxidative stress reduction, and overall therapeutic efficacy compared to the control group. In addition, the observation group showed more pronounced reductions in obesity indices, BS levels, lipid profiles, BP, and PANSS scores. However, improvements in quality-of-life were comparable between the two groups.
Conclusion: CB0313.1 helps enhance the clinical management of MS in schizophrenic patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
